N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N3-dodecylpyrazine-2,3-dicarboxamide | 1188923-42-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N3-dodecylpyrazine-2,3-dicarboxamide
• 英文别名: 3-N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-N-dodecylpyrazine-2,3-dicarboxamide
• CAS: 1188923-42-3
• 化学式: C₂₇H₃₈F₂N₆O₆
• 分子量: 580.632
• InChiKey: VIXLTTSVDIPGNX-YBGOQADZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  41
• 可旋转键数：
  16
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  166
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-(dodecylcarbamoyl)pyrazine-2-carboxylic acid 、 盐酸吉西他滨 在 4-二甲氨基吡啶 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N3-dodecylpyrazine-2,3-dicarboxamide
  参考文献：
  名称：

  Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof

  摘要：

  基于吉西他滨结构的前药，如式（I）所示，以及它们的合成方法和应用在本发明中被揭示，其中a、b、c、d、E、Z和V的定义在说明书中描述。通过修改N4基团，改善了前药的溶解性、生物利用度和器官特异性。因此，生产的前药化合物克服了快速代谢问题。吉西他滨引起的肠道毒性减少。因此，前药可以通过口服在临床中投递，并进一步提高其抗肿瘤、抗癌、抗感染和扩散预防能力，还可以特异性地作用于肝脏或结肠。合成方法简单，适用于工业生产。

  公开号：

  US20120088908A1

文献信息

• PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF
  申请人：Sanlugen Pharmatech Ltd.

  公开号：EP2423215A1

  公开（公告）日：2012-02-29

  Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.

  本发明公开了基于式（I）所示吉西他滨结构的原药及其合成方法和应用，其中a、b、c、d、E、Z和V基团的定义已在说明书中描述。通过修改 N4 基团，原药的溶解度、生物利用度和器官特异性都得到了改善。因此，所生产的原药化合物克服了快速代谢的问题。吉西他滨引起的肠道毒性也会降低。因此，该原药可在临床上通过口服给药，进一步提高其抗肿瘤、抗癌、抗感染和防扩散能力，还能特异性地作用于肝脏或结肠。合成方法简单，适合工业化生产。
• EP2423215
  申请人：——

  公开号：——

  公开（公告）日：——
• US8653048B2
  申请人：——

  公开号：US8653048B2

  公开（公告）日：2014-02-18
• Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof
  申请人：Xue Xiaoxia

  公开号：US20120088908A1

  公开（公告）日：2012-04-12

  Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N 4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.

  基于吉西他滨结构的前药，如式（I）所示，以及它们的合成方法和应用在本发明中被揭示，其中a、b、c、d、E、Z和V的定义在说明书中描述。通过修改N4基团，改善了前药的溶解性、生物利用度和器官特异性。因此，生产的前药化合物克服了快速代谢问题。吉西他滨引起的肠道毒性减少。因此，前药可以通过口服在临床中投递，并进一步提高其抗肿瘤、抗癌、抗感染和扩散预防能力，还可以特异性地作用于肝脏或结肠。合成方法简单，适用于工业生产。